Gary Patou sold $201k of XENE
director at Xenon Pharmaceuticals Inc.. 4,891 shares at an average of $41.09, traded Nov 22, 2024, filed Nov 22, 2024.
Score components
- +15RoleDirector
- +12Trade size$201k at market
- +5Share of holdings soldSold 19% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-130378, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | MOption exercise Common Shares | +3,500 | $7.38 | $26k | 27,073 | Nov 22, 2024 |
| Nov 22, 2024 | FTax withholding Common Shares | -649 | $39.80 | $26k | 26,424 | Nov 22, 2024 |
| Nov 22, 2024 | SOpen-market sale Common Shares | -2,851 | $41.11 | $117k | 23,573 | Nov 22, 2024 |
| Nov 22, 2024 | MOption exercise Common Shares | +3,086 | $13.48 | $42k | 26,659 | Nov 22, 2024 |
| Nov 22, 2024 | FTax withholding Common Shares | -1,046 | $39.80 | $42k | 25,613 | Nov 22, 2024 |
| Nov 22, 2024 | SOpen-market sale Common Shares | -2,040 | $41.05 | $84k | 23,573 | Nov 22, 2024 |
| Nov 22, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -3,500 | $0.00 | $0 | 0 | Nov 22, 2024 |
| Nov 22, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -3,086 | $0.00 | $0 | 0 | Nov 22, 2024 |
Related signals
Other insiders at Xenon Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 75Notable | Xenon Pharmaceuticals Inc. | Thomas Patrick Kelly Chief Financial Officer | $560k 15,000 shares | - | |
| 86Strong | Xenon Pharmaceuticals Inc. | Ian Mortimer PRESIDENT & CEO | $1.1M 30,000 shares | +151% | |
| 15Weak | XENEsell Xenon Pharmaceuticals Inc. | Steven Gannon director | $91 3 shares | -0% | |
| 49Moderate | XENEsell Xenon Pharmaceuticals Inc. | Sherry Aulin Chief Financial Officer | $771k 18,709 shares | -260% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.